EIM
ALNY icon

Essex Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Essex Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-13,365
Closed -$1.17M – 479
2018
Q3 		$1.17M Buy
+13,365
New +$1.34M 0.14% 207
2016
Q1 		– Sell
-7,244
Closed -$682K – 313
2015
Q4 		$682K Sell
7,244
-11,000
-60% -$1.02M 0.11% 206
2015
Q3 		$1.47M Buy
18,244
+11,000
+152% +$1.22M 0.24% 94
2015
Q2 		$868K Sell
7,244
-580
-7% -$69.3K 0.13% 174
2015
Q1 		$817K Buy
7,824
+3,816
+95% +$387K 0.11% 183
2014
Q4 		$389K Sell
4,008
-669
-14% -$62K 0.06% 255
2014
Q3 		$365K Buy
4,677
+1,516
+48% +$97.8K 0.06% 266
2014
Q2 		$200K Hold
3,161
– – 0.03% 334
2014
Q1 		$212K Sell
3,161
-1,188
-27% -$92K 0.03% 324
2013
Q4 		$280K Buy
4,349
+1,188
+38% +$70.9K 0.04% 322
2013
Q3 		$202K Buy
+3,161
New +$158K 0.03% 338

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Essex Investment Management's ALNY Position: Q4 2018 in Review

Essex Investment Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2018, closing a stake of 13,365 shares — an estimated $1.17M sold.

Essex Investment Management first reported a position in ALNY in Q3 2013 and held it in 11 quarters. The position peaked at $1.47M in Q3 2015. 284 funds tracked by Wall St. Rank hold ALNY as of Q4 2018.

  • Essex Investment Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Essex Investment Management sold 13,365 Alnylam Pharmaceuticals shares in Q4 2018, an estimated $1.17M.
  • Essex Investment Management first reported a position in Alnylam Pharmaceuticals in Q3 2013 and held it in 11 quarters.
  • Essex Investment Management's Alnylam Pharmaceuticals position peaked at $1.47M in Q3 2015.
  • 284 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2018.

Based on Essex Investment Management's 13F filing for Q4 2018, filed 6 Feb 2019.